This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Distinct evolution of infection-enhancing and neutralizing epitopes in the spike protein of SARS-CoV-2 variants (alpha, beta, gamma, delta, lambda and mu) : a structural and molecular epidemiology study
Patrick GUERIN, Nouara YAHI, Fodil AZZAZ, Henri CHAHINIAN, Jean-Marc SABATIER, Jacques FANTINI
This work is licensed under a CC BY 4.0 License. Read Full License
Objectives. The efficiency of Covid-19 vaccination is determined by cellular and humoral immune responses, and for the latter, by the balance between neutralizing and infection-enhancing antibodies. Here we analyzed the evolution of neutralizing and facilitating epitopes in the spike protein among SARS-CoV-2 variants. Methods. Amino acid alignments were performed on 929,203 spike sequences over the 4 last months. Molecular modeling studies of the N-terminal domain (NTD) and rod-like regions of the spike protein were performed on a representative panel of SARS-CoV-2 variants that were structurally compared with the original Wuhan strain. Results. D614, which belongs to an antibody-dependent-enhancement (ADE) epitope common to SARS-CoV-1 and SARS-CoV-2, has rapidly mutated to D614G in the first months of 2020, explaining why ADE has not been detected following mass vaccination. We show that this epitope is conformationally linked to the main ADE epitope of the SARS-CoV-2 NTD which is highly conserved among most variants. In contrast, the neutralizing epitope of the NTD showed extensive variations in SARS-CoV-2 variants. Conclusions. This molecular epidemiology study coupled with structural analysis of the spike protein indicates that the balance between facilitating and neutralizing antibodies in vaccinated people is in favor of neutralization for the Wuhan strain,alpha and beta variants, but not for gamma, delta, lambda and mu. The evolution of SARS-CoV-2 has dramatically affected the ADE/neutralization balance which is nowadays in favor of ADE. Future vaccines should consider these data to design new formulations adapted to SARS-CoV-2 variants and lacking ADE epitopes in the spike protein.
SARS-CoV-2 variants, vaccine, facilitating antibodies, neutralizing antibodies, molecular epidemiology
commented on 19 November, 2021
j’ai 72 ans, ai eu la Covid en clinique, ai eu un premier vaccin et très bientôt je dois procéder au deuxième rappel. j’entre dans la catégorie des personnes fragilisées. Bronchites à répétition et je pèse 100 kg. Ma question : dois-je procéder au deuxième rappel ? je ne sais plus ce qui est bon ou mauvais pour moi.
View 1 reply
commented on 20 November, 2021
María Eugenia Canchi
commented on 22 November, 2021
No creo en la efectividad de las vacunas, en contra del Covid’19; más dudo mucho de las mismas y temo de sus respectivas reacciones o efectos adversos, que las mismas podrían producir en mi organismo, a futuro!!!
Comments can take the form of short reviews, notes, or questions to the author and are posted immediately. Comments may be removed based on:reports from the communityautomated detection of potentially problematic words or linksautomated detection by our spam filterAutomatic moderation of comments occurs shortly after posting. Comments that are removed as a result are reviewed daily and only reinstated if deemed appropriate by our staff. If you think a comment has been hidden or unhidden mistakenly, please contact us at email@example.com.